COPD News Quiz: A Few Good Questions

May 7th 2025

AstraZeneca's Triple Inhaled Therapy Meets Primary Endpoints in Phase 3 Trials of Uncontrolled Asthma

The model demonstrated 70.63% accuracy for predicting depression, a common comorbidity seen in COPD and one that increases risk for negative outcomes.

AstraZeneca's Triple Inhaled Therapy Meets Primary Endpoints in Phase 3 Asthma Trials / image credit Alberto Papi, MD, PhD Ferarra University Italy

May 2nd 2025

New Data on Dupilumab Reinforces Its Impact on Chronic Respiratory Diseases

The KALOS and LOGOS registration trials in patients with uncontrolled asthma compared the triple fixed dose BGF with dual combination therapy.

Mepolizumab Reduces AER in COPD Leading to Emergency Care by 35%: MATINEE Findings Published in NEJM

New clinical trial findings to be presented at ATS 2025 highlights the effectiveness of dupilumab in treating COPD and asthma.

Mepolizumab Reduces Annualized COPD Exacerbation Rate Leading to Emergency Care by 35% image credit ©desertsands/stock.adobe.com

Perceived Stress Tied to Worsened Respiratory Outcomes, Decreased QoL in Adults with COPD

Mepolizumab also cut annualized exacerbation rates by 21% across the full study cohort and by 31% in a subgroup of participants with chronic bronchitis only.

April 30th 2025

Untreated Depression, Anxiety Worsen COPD Outcomes: Daily Dose

Researchers reported higher levels of perceived stress were associated with worse respiratory outcomes, particularly among individuals with severe COPD.

April 21st 2025

Machine Learning Model Effectively Predicts Depression Risk in Adults with COPD

Your daily dose of the clinical news you may have missed.

Related Content

May 7th 2025

AstraZeneca's Triple Inhaled Therapy Meets Primary Endpoints in Phase 3 Trials of Uncontrolled Asthma

The model demonstrated 70.63% accuracy for predicting depression, a common comorbidity seen in COPD and one that increases risk for negative outcomes.

May 2nd 2025

New Data on Dupilumab Reinforces Its Impact on Chronic Respiratory Diseases

The KALOS and LOGOS registration trials in patients with uncontrolled asthma compared the triple fixed dose BGF with dual combination therapy.

Mepolizumab Reduces AER in COPD Leading to Emergency Care by 35%: MATINEE Findings Published in NEJM

New clinical trial findings to be presented at ATS 2025 highlights the effectiveness of dupilumab in treating COPD and asthma.

Perceived Stress Tied to Worsened Respiratory Outcomes, Decreased QoL in Adults with COPD

Mepolizumab also cut annualized exacerbation rates by 21% across the full study cohort and by 31% in a subgroup of participants with chronic bronchitis only.

April 30th 2025

Untreated Depression, Anxiety Worsen COPD Outcomes: Daily Dose

Researchers reported higher levels of perceived stress were associated with worse respiratory outcomes, particularly among individuals with severe COPD.

April 21st 2025